A.C.T. Holdings, Inc.

Cloning, cellular reprogramming agreements signed

Published in Medicine and Law Weekly, July 1st, 2005

A.C.T. Holdings, Inc., (ACTH) and its wholly-owned subsidiary, Advanced Cell Technology, Inc., (ACT) announced that ACT has entered into two separate agreements to expand its portfolio of intellectual property in regard to somatic cell nuclear transfer (SCNT) and cellular reprogramming.

In the first agreement, ACT acquired an option to exclusively license cloning patents from TranXenoGen, Inc., of Shrewsbury, Massachusetts. The patents include U.S. patents 5,480,772; 5,651,992; 5,773,217; 6,245,567; 6,753,457; and 6,878,546. This patent family includes granted claims related to somatic cell nuclear transfer and the use of oocytes and oocyte extracts to reprogram somatic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-07-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry